Communiqués Ensysce Biosciences, Inc.

Actions

ENSC

US2936024056

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 15/07/2024			Varia. 5j.	Varia. 1 janv.
0,4615 ^USD	+0,22 %		-0,41 %	-56,46 %

28/05	Ensysce Biosciences de nouveau en conformité avec le Nasdaq	MT
20/05	Mise à jour sectorielle : Les actions du secteur de la santé plus douces en fin d'après-midi	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Ensysce Biosciences Hosts IASP 2024 Symposium and Presents Clinical Dataset	10/07	AQ
Ensysce Biosciences Discusses Key Themes from the EPHMRA 2024 Annual Meeting	28/06	AQ
Ensysce Biosciences Announces Partnership to Scale and Manufacture New Drug Candidate	26/06	AQ
Ensysce Biosciences Announces Major Milestone for Opioid Use Disorder Program	07/06	AQ
Ensysce Biosciences Regains Compliance with Nasdaq	29/05	AQ
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform	21/05	AQ
Ensysce Biosciences Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published	22/04	AQ
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference	10/04	AQ
Ensysce Biosciences : Corporate Overview	28/03	PU
Ensysce Biosciences Receives Positive Nasdaq Listing Determination	28/02	AQ
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $4.7 Million Gross Proceeds	14/02	AQ
Ensysce Biosciences Selected to Present at American Association of Pain Medicine Annual Conference	07/02	AQ
Ensysce Biosciences to Present Groundbreaking Oral Overdose Protection for Opioids at the 5th Annual NIH HEAL Meeting	26/01	AQ
Ensysce Biosciences Announces FDA Breakthrough Therapy Designation Granted for PF614-MPAR	24/01	AQ
Ensysce Biosciences Issues 2024 Shareholder Letter	09/01	AQ
Ensysce Biosciences Postpones Special Meeting of Stockholders to December 29, 2023	20/12	AQ
Ensysce Biosciences Announces Key Efficacy Data for Lead Analgesic	15/12	AQ
Ensysce Biosciences Discusses TAAP and MPAR Applications and OncoZenge Partnership with the Stock Day Podcast	12/12	AQ
Ensysce Biosciences Announces Completion of $1.7 Million Convertible Note Financing	30/11	AQ
Ensysce Biosciences and OncoZenge Announce Letter of Intent for the Co-development of BupiZenge™ in the United States	28/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Ensysce Biosciences, Inc.

Actions

ENSC

US2936024056

Communiqués

Filtres